Contineum Therapeutics (CTNM) Institutional Ownership $5.66 +0.16 (+2.82%) As of 12:35 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Contineum Therapeutics (NASDAQ:CTNM)Number ofInstitutional Buyers(last 12 months)37TotalInstitutional Inflows(last 12 months)$130.88MNumber ofInstitutional Sellers(last 12 months)8TotalInstitutional Outflows(last 12 months)$12.51M Get CTNM Insider Trade Alerts Want to know when executives and insiders are buying or selling Contineum Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data CTNM Institutional Buying and Selling by Quarter Contineum Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails6/27/2025Goldman Sachs Group Inc.14,221$99K0.0%-46.1%0.055% 5/28/2025Strs Ohio3,900$27K0.0%N/A0.015% 5/16/2025Goldman Sachs Group Inc.14,221$99K0.0%-46.1%0.055% 5/16/2025Dynamic Technology Lab Private Ltd16,838$118K0.0%N/A0.065% 5/16/2025ADAR1 Capital Management LLC168,765$1.18M0.2%+105.2%0.652% 5/13/2025Altium Capital Management LLC303,857$2.12M5.1%-9.0%1.174% 5/12/2025Nuveen LLC13,307$93K0.0%N/A0.051% 5/9/2025Charles Schwab Investment Management Inc.51,202$357K0.0%-7.5%0.198% 2/17/2025Squarepoint Ops LLC217,239$3.18M0.0%-37.9%0.843% 2/17/2025Stempoint Capital LP265,833$3.89M1.0%N/A1.031% Get the Latest News and Ratings for CTNM and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Contineum Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/17/2025 Red Tree Management LLC638,158$9.35M6.2%N/A2.475% 2/17/2025Polar Capital Holdings Plc43,604$639K0.0%-79.9%0.169% 2/17/2025Nuveen Asset Management LLC13,307$195K0.0%N/A0.052% 2/17/2025MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.5,860$86K0.0%+90.4%0.023% 2/17/2025Janus Henderson Group PLC68,320$1.00M0.0%N/A0.265% 2/17/2025Deutsche Bank AG16,079$236K0.0%N/A0.062% 2/17/2025Bank of America Corp DE9,132$134K0.0%+63.4%0.035% 2/14/2025Schonfeld Strategic Advisors LLC125,995$1.85M0.0%N/A0.489% 2/14/2025Northern Trust Corp89,262$1.31M0.0%+42.3%0.346% 2/14/2025MetLife Investment Management LLC7,029$103K0.0%N/A0.027% 2/14/2025Altium Capital Management LLC334,000$4.89M1.4%-9.5%1.296% 2/13/2025Marshall Wace LLP10,836$159K0.0%N/A0.042% 2/13/2025Strategies Wealth Advisors LLC25,000$366K0.0%N/A0.097% 2/13/2025Barclays PLC16,286$239K0.0%+96.0%0.063% 2/13/2025Legal & General Group Plc3,631$53K0.0%+74.0%0.014% 2/13/2025ADAR1 Capital Management LLC82,234$1.21M0.2%+817.1%0.319% 2/13/2025Wells Fargo & Company MN10,755$158K0.0%+419.3%0.042% 2/12/2025Geode Capital Management LLC188,408$2.76M0.0%+46.4%0.731% 2/12/2025Franklin Resources Inc.1,445,565$21.18M0.0%-0.1%5.607% 2/12/2025Norges Bank169,729$2.49M0.0%N/A0.658% 2/12/2025JPMorgan Chase & Co.28,426$416K0.0%+1,040.7%0.110% 2/12/2025WINTON GROUP Ltd39,738$582K0.0%+256.8%0.154% 2/11/2025Corebridge Financial Inc.5,215$76K0.0%+73.1%0.020% 2/6/2025Charles Schwab Investment Management Inc.55,330$811K0.0%+27.8%0.215% 2/4/2025Bank of New York Mellon Corp18,738$275K0.0%+32.3%0.073% 1/30/2025Rhumbline Advisers8,233$121K0.0%+36.3%0.032% 11/27/2024Franklin Resources Inc.1,447,550$27.71M0.0%+130.9%5.615% 11/19/2024Barclays PLC8,308$158K0.0%+248.6%0.032% 11/16/2024Geode Capital Management LLC128,676$2.46M0.0%-17.7%0.500% 11/15/2024Barclays PLC8,308$158K0.0%+248.6%0.032% I warned you about Nvidia… now look what’s happening (Ad)Nvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before the open. That’s the kind of move Tim Sykes built his XGPT system to trade. It scans AI news in real time, filters the noise, and pinpoints when to strike. He’s now showing exactly how it works — before the next headline hits.Watch how Tim Sykes trades AI headlines for real gains11/15/2024State Street Corp113,566$2.17M0.0%+23.7%0.442% 11/14/2024Suvretta Capital Management LLC1,720,000$32.92M1.1%-16.2%6.687% 11/13/2024BNP Paribas Financial Markets6,743$129K0.0%+1,248.6%0.026% 11/13/2024FMR LLC696,927$13.34M0.0%+115.4%2.710% 11/12/2024Charles Schwab Investment Management Inc.43,295$829K0.0%-16.4%0.168% 8/16/2024Perceptive Advisors LLC1,566,668$27.59M0.7%N/A6.091% 8/16/2024Driehaus Capital Management LLC66,667$1.17M0.0%N/A0.259% 8/14/2024Squarepoint Ops LLC150,000$2.64M0.0%N/A0.583% 8/14/2024Sandia Investment Management LP5,000$88K0.1%N/A0.019% 8/9/2024 Johnson & Johnson1,979,173$34.85M8.7%N/A7.694% 8/8/2024Versant Venture Management LLC918,163$16.17M20.9%N/A3.569% 8/1/2024Rhumbline Advisers6,722$118K0.0%N/A0.026% 7/26/2024Bank of New York Mellon Corp20,232$356K0.0%N/A0.079% (Data available from 1/1/2016 forward) CTNM Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CTNM shares? During the previous two years, 41 institutional investors and hedge funds held shares of Contineum Therapeutics. The most heavily invested institutionals were Johnson & Johnson ($34.85M), Suvretta Capital Management LLC ($32.92M), Perceptive Advisors LLC ($27.59M), Franklin Resources Inc. ($21.18M), Versant Venture Management LLC ($16.17M), FMR LLC ($13.34M), and Red Tree Management LLC ($9.35M).Learn more on Contineum Therapeutics' institutional investors. Which institutional investors have been buying Contineum Therapeutics' stock? Of the 37 institutional investors that purchased Contineum Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Johnson & Johnson ($1.98M), Perceptive Advisors LLC ($1.57M), Versant Venture Management LLC ($918.16K), Franklin Resources Inc. ($820.54K), Red Tree Management LLC ($638.16K), FMR LLC ($373.33K), and Stempoint Capital LP ($265.83K). How much institutional buying is happening at Contineum Therapeutics? Institutional investors have bought a total of 7,666,821 shares in the last 24 months. This purchase volume represents approximately $130.88M in transactions. Which of Contineum Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold Contineum Therapeutics stock in the last 24 months: Suvretta Capital Management LLC ($333.33K), Polar Capital Holdings Plc ($173.00K), Squarepoint Ops LLC ($132.76K), Altium Capital Management LLC ($65.27K), Geode Capital Management LLC ($27.75K), Goldman Sachs Group Inc. ($24.29K), and Charles Schwab Investment Management Inc. ($12.61K). How much institutional selling is happening at Contineum Therapeutics? Institutional investors have sold a total of 770,984 shares in the last 24 months. This volume of shares sold represents approximately $12.51M in transactions. Related Companies ITOS Institutional Ownership ETON Institutional Ownership VIGL Institutional Ownership CYRX Institutional Ownership HUMA Institutional Ownership CKPT Institutional Ownership ATXS Institutional Ownership ARCT Institutional Ownership BNTC Institutional Ownership GOSS Institutional Ownership This page (NASDAQ:CTNM) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Contineum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Contineum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
